Daniel Yick Chin Heng

Author

Also Known As

D Heng, D. Heng, D.Y. Heng, D.Y.C. Heng, Daizhong Heng, Daniel Heng, Daniel Y C Heng, Daniel Y Heng, Daniel Y. C. Heng, Daniel Y. Heng

171

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

University of Calgary Dana-Farber Cancer Institute Princess Margaret Cancer Centre BC Cancer Agency Cleveland Clinic

About

Daniel Yick Chin Heng is an author at University of Calgary specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	676
2	Immunology	4	4	325
3	Health Sciences	2	2	151
4	Public Health	1	1	18
5	Biostatistics	1	1	18

Daniel Yick Chin Heng

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. Daniel Yick Chin Heng, Linda Sharples, K. McNeil, PubMed	1998	296
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy Ali Golshayan, Saby George, Daniel Yick Chin Heng, Journal of Clinical Oncology	2008	229
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium Silke Gillessen, Nicolas Sauvé, Laurence Collette, Journal of Clinical Oncology	2021	220
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations Laurence Albigès, A. Ari Hakimi, Wanling Xie, Journal of Clinical Oncology	2016	211
Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group Judith Manola, Patrick Royston, Paul Elson, Clinical Cancer Research	2011	184
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer Toni K. Choueiri, Elizabeth R. Plimack, Hendrik-Tobias Arkenau, Journal of Clinical Oncology	2017	172
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium J. Beyer, Laurence Collette, Nicolas Sauvé, Journal of Clinical Oncology	2021	160
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy Arnoud J. Templeton, Jennifer J. Knox, Xun Lin, European Urology UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineImmunology	2016	147
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Journal of Clinical Oncology ImmunologyImmunotherapeuticsImmunotherapy↑ AmylaseTumor Immunology	2014	139
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors Sarah Cook, Vanessa Samuel, Daniel E. Meyers, JAMA Network Open	2024	121

Page 1